Foghorn Therapeutics Inc. announced on September 25, 2026, that it and its partner Eli Lilly and Company have decided not to advance the clinical development of the drug candidate FHD-909 into the expansion phase. This decision was made following a review of clinical data from the Phase 1 dose escalation trial of FHD-909 (LY4050784). The companies also stated that they do not anticipate further collaboration activities regarding the Selective SMARCA2 degrader program.
Foghorn stated that the biology of the SMARCA2/4 synthetic lethality relationship did not translate into the level of efficacy required to further advance the program. The company emphasized that it is prioritizing resources toward its proprietary portfolio programs with the greatest potential to address significant patient needs.
In connection with this strategic shift, Foghorn’s Board of Directors approved a reprioritization and workforce reduction on September 30, 2026. The company announced a reduction in its workforce by approximately 40%. Foghorn expects to substantially complete this reduction in the fourth quarter of 2026, resulting in approximately 65 full-time employees.
The company estimates that it will incur aggregate charges of approximately $2.3 million related to these changes, all of which are anticipated to result in future cash expenditures. These costs are primarily for one-time employee severance and benefit costs, expected to be incurred in the fourth quarter of 2026. Foghorn stated that these organizational changes are expected to extend its cash runway into the second half of 2029.
